Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1966 Nov 26;95(22):1120–1127.

The Treatment of Gout and Disorders of Uric Acid Metabolism with Allopurinol

M A Ogryzlo, M B Urowitz, H M Weber, J B Houpt
PMCID: PMC1935821  PMID: 5923471

Abstract

Allopurinol (4-hydroxypyrazolo (3,4-d)-pyrimidine) is a potent xanthine oxidase inhibitor which inhibits the oxidation of naturally occurring oxypurines, thus decreasing uric acid formation. The clinical and metabolic effects of this agent were studied in 80 subjects with primary and secondary gout and other disorders of uric acid metabolism. Allopurinol has been universally successful in lowering the serum uric acid concentration and uric acid excretion to normal levels, while not significantly affecting the clearance of urate or other aspects of renal function. Oxypurine excretion increased concomitantly with the fall in urine uric acid. The agent is particularly valuable in the management of problems of gout with azotemia, acute uric acid nephropathy and uric acid urolithiasis. The minor side effects, clinical indications and theoretical complications are discussed.

Full text

PDF
1120

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BISHOP C. [The renal regulation of urate excretion and its relationship to the etiology of gout]. Arch Interam Rheumatol. 1962 Mar;5:5–15. [PubMed] [Google Scholar]
  2. DENT C. E., PHILPOT G. R. Xanthinuria, an inborn error (or deviation) of metabolism. Lancet. 1954 Jan 23;266(6804):182–185. doi: 10.1016/s0140-6736(54)91257-x. [DOI] [PubMed] [Google Scholar]
  3. DICKINSON C. J., SMELLIE J. M. Xanthinuria. Br Med J. 1959 Dec 5;2(5161):1217–1221. doi: 10.1136/bmj.2.5161.1217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DeConti R. C., Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med. 1966 Mar 3;274(9):481–486. doi: 10.1056/NEJM196603032740902. [DOI] [PubMed] [Google Scholar]
  5. ENGELMAN K., WATTS R. W., KLINENBERG J. R., SJOERDSMA A., SEEGMILLER J. E. CLINICAL, PHYSIOLOGICAL AND BIOCHEMICAL STUDIES OF A PATIENT WITH XANTHINURIA AND PHEOCHROMOCYTOMA. Am J Med. 1964 Dec;37:839–861. doi: 10.1016/0002-9343(64)90128-7. [DOI] [PubMed] [Google Scholar]
  6. FEIGELSON P., DAVIDSON J. D., ROBINS R. K. Pyrazolopyrimidines as inhibitors and substrates of xanthine oxidase. J Biol Chem. 1957 Jun;226(2):993–1000. [PubMed] [Google Scholar]
  7. FREI E., 3rd, BENTZEL C. J., RIESELBACH R., BLOCK J. B. RENAL COMPLICATIONS OF NEOPLASTIC DISEASE. J Chronic Dis. 1963 Jul;16:757–776. doi: 10.1016/0021-9681(63)90010-9. [DOI] [PubMed] [Google Scholar]
  8. GRAYZEL A. I., SEEGMILLER J. E., LOVE E. Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-L-norleucine. J Clin Invest. 1960 Mar;39:447–454. doi: 10.1172/JCI104057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. GREENBAUM D., STONE H. F. H. Dangers of uric-acid excretion during treatment of leukaemia and lymphosarcoma. Lancet. 1959 Jan 10;1(7063):73–75. doi: 10.1016/s0140-6736(59)91140-7. [DOI] [PubMed] [Google Scholar]
  10. GUTMAN A. B., YU T. F. Renal function in gout; with a commentary on the renal regulation of urate excretion, and the role of the kidney in the pathogenesis of gout. Am J Med. 1957 Oct;23(4):600–622. doi: 10.1016/0002-9343(57)90231-0. [DOI] [PubMed] [Google Scholar]
  11. HALL A. P., HOLLOWAY V. P., SCOTT J. T. 4-HYDROXYPYRAZOLO (3,4-D) PYRIMIDINE (HPP) IN THE TREATMENT OF GOUT: PRELIMINARY OBSERVATIONS. Ann Rheum Dis. 1964 Nov;23:439–446. doi: 10.1136/ard.23.6.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. HAUGEN H. N., BLEGEN E. M. The true endogenous creatinine clearance. Scand J Clin Lab Invest. 1953;5(1):67–71. doi: 10.3109/00365515309093514. [DOI] [PubMed] [Google Scholar]
  13. Houpt J. B. The effect of allopurinol (HPP) in the treatment of gout. Arthritis Rheum. 1965 Oct;8(5):899–904. doi: 10.1002/art.1780080455. [DOI] [PubMed] [Google Scholar]
  14. KLINENBERG J. R., GOLDFINGER S. E., SEEGMILLER J. E. THE EFFECTIVENESS OF THE XANTHINE OXIDASE INHIBITOR ALLOPURINOL IN THE TREATMENT OF GOUT. Ann Intern Med. 1965 Apr;62:639–647. doi: 10.7326/0003-4819-62-4-639. [DOI] [PubMed] [Google Scholar]
  15. KRAKOFF I. H., MEYER R. L. PREVENTION OF HYPERURICEMIA IN LEUKEMIA AND LYMPHOMA: USE OF ALOPURINOL, A XANTHINE OXIDASE INHIBITOR. JAMA. 1965 Jul 5;193:1–6. doi: 10.1001/jama.1965.03090010007001. [DOI] [PubMed] [Google Scholar]
  16. KRITZLER R. A. Anuria complicating the treatment of leukemia. Am J Med. 1958 Oct;25(4):532–538. doi: 10.1016/0002-9343(58)90042-1. [DOI] [PubMed] [Google Scholar]
  17. Krakoff I. H. Studies of uric acid biosynthesis in the chronic leukemias. Arthritis Rheum. 1965 Oct;8(5):772–779. doi: 10.1002/art.1780080440. [DOI] [PubMed] [Google Scholar]
  18. OGRYZLO M. A. The renal factor in the etiology of primary gout. Can Med Assoc J. 1960 Dec 17;83:1326–1327. [PMC free article] [PubMed] [Google Scholar]
  19. POMALES R., BIEBER S., FRIEDMAN R., HITCHINGS G. H. Augmentation of the incorporation of hypoxanthine into nucleic acids by the administration of an inhibitor of xanthine oxidase. Biochim Biophys Acta. 1963 May 28;72:119–120. [PubMed] [Google Scholar]
  20. Powell L. W., Emmerson B. T. Haemosiderosis associated with xanthine oxidase inhibition. Lancet. 1966 Jan 29;1(7431):239–240. doi: 10.1016/s0140-6736(66)90056-0. [DOI] [PubMed] [Google Scholar]
  21. Rundles R. W., Metz E. N., Silberman H. R. Allopurinol in the treatment of gout. Ann Intern Med. 1966 Feb;64(2):229–258. doi: 10.7326/0003-4819-64-2-229. [DOI] [PubMed] [Google Scholar]
  22. SEEGMILLER J. E., GRAYZEL A. I., LASTER L., LIDDLE L. Uric acid production in gout. J Clin Invest. 1961 Jul;40:1304–1314. doi: 10.1172/JCI104360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. SEEGMILLER J. E., LASTER L., HOWELL R. R. Biochemistry of uric acid and its relation to gout. N Engl J Med. 1963 Apr 4;268:764–contd. doi: 10.1056/NEJM196304042681406. [DOI] [PubMed] [Google Scholar]
  24. SORENSEN L. B. The pathogenesis of gout. Arch Intern Med. 1962 Apr;109:379–390. doi: 10.1001/archinte.1962.03620160005002. [DOI] [PubMed] [Google Scholar]
  25. Smyth C. J. Studies with allopurinol (HPP) in patients with tophaceous gout. Arthritis Rheum. 1965 Oct;8(5):907–910. doi: 10.1002/art.1780080457. [DOI] [PubMed] [Google Scholar]
  26. WEISBERGER A. S., PERSKY L. Renal calculi and uremia as complications of lymphoma. Am J Med Sci. 1953 Jun;225(6):669–673. doi: 10.1097/00000441-195306000-00012. [DOI] [PubMed] [Google Scholar]
  27. WESTERFELD W. W., RICHERT D. A., HILFINGER M. F. Studies on xanthine oxidase during carcinogenesis by p-dimethylaminoazobenzene. Cancer Res. 1950 Aug;10(8):486–494. [PubMed] [Google Scholar]
  28. WYNGAARDEN J. B. On the dual etiology of hyperuricemia in primary gout. Arthritis Rheum. 1960 Oct;3:414–420. doi: 10.1002/art.1780030507. [DOI] [PubMed] [Google Scholar]
  29. WYNGAARDEN J. B., RUNDLES R. W., METZ E. N. ALLOPURNOL IN THE TREATMENT OF GOUT. Ann Intern Med. 1965 Apr;62:842–847. doi: 10.7326/0003-4819-62-4-842. [DOI] [PubMed] [Google Scholar]
  30. Wyngaarden J. B. Xanthine oxidase inhibitors in the management of gout. Arthritis Rheum. 1965 Oct;8(5):883–890. doi: 10.1002/art.1780080452. [DOI] [PubMed] [Google Scholar]
  31. Yü T. F. The effect of allopurinol in primary and secondary gout. Arthritis Rheum. 1965 Oct;8(5):905–906. doi: 10.1002/art.1780080456. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES